Monoclonal antibodies will lead biologics sales through 2035 with 65.1% share of the drug class segment in 2025. Oncology holds 32.4% share of the application segment in 2025. The market is expected to reach USD 450.2 billion in 2025 and USD 1,077.2 billion by 2035 across major therapy areas.